HDAC3 and cholangiocarcinoma: We found that HDACs inhibitor treatment did not significantly change the cellular localization or protein levels of HDAC3 in CCA cells and xenograft samples, indicating that the inhibition of HDAC3 activity, instead of its expression and phosphorylation, contributed to the anti-tumor effect of the inhibitor.